An efficacious vaccine against adult tuberculosis (TB) remains elusive. Progress is hampered by an incomplete understanding of the immune mechanisms that protect against infection with Mycobacterium tuberculosis (Mtb), the causative agent of TB 1 . Over 90% of people who become infected with Mtb mount an immune response that contains the bacteria indefinitely, leading to a state known as "latent TB infection" (LTBI) 2 . A significant body of epidemiologic evidence indicates that LTBI protects against active TB after re-exposure, offering an intriguing avenue to identifying protective mechanisms 3,4 . We show that in a mouse model, LTBI is highly protective against infection with Mtb for up to 100 days following aerosol challenge. LTBI mice are also protected against heterologous bacterial challenge (Listeria monocytogenes) and disseminated melanoma suggesting that protection is in part mediated by alterations in the activation state of the innate immune system. Protection is associated with elevated activation of alveolar macrophages (AM), the first cells that respond to inhaled Mtb, and accelerated recruitment of Mtb-specific T cells to the lung parenchyma upon aerosol challenge. Systems approaches, including transcriptome analysis of both naïve and infected AMs, as well as ex vivo functional assays, demonstrate that LTBI reconfigures the response of tissue resident AMs.. Furthermore, we demonstrate that both LTBI mice and latently infected humans show similar alterations in the relative proportions of circulating innate immune cells, suggesting that the same cellular changes observed in the LTBI mouse model are also occurring in humans. Therefore, we argue that under certain circumstances, LTBI could be beneficial to the host by providing protection against subsequent Mtb exposure. * * CD11b PerCPCy5.5
Introduction
The failure to identify mechanisms or correlates of protection against TB has hampered the development of vaccines or host-directed therapies to combat the world-wide disease burden which is estimated to be 10.4 million cases and 1.8 million deaths annually 5 . The immune mechanisms that protect against TB are evidently quite powerful: Due to the extraordinarily high prevalence of Mycobacterium tuberculosis (Mtb) (some estimates suggest that at least 25% of the world's population has been exposed 2 ) TB ranks as the deadliest infectious disease world-wide. However, the vast majority (~90%) of individuals with an intact immune system are able to contain and control the infection for their lifetimes with no clinical symptoms leading to a state known as "latent TB infection" 2 .
LTBI is clinically defined as the presence of an Mtb-specific adaptive immune response in the absence of signs and symptoms of disease. It is widely believed that the clinical definition encompasses a variety of disease states, often referred to as the "spectrum of TB disease", including bacterial clearance, persistence of live bacteria contained by the immune system, and subclinical disease 6 , 7 . It is clear that humans may harbor viable Mtb in a variety of tissues for decades without developing symptoms [8] [9] [10] [11] . In both humans 12 and non-human primates 13 , the lymphatic system plays key roles in the spectrum of disease by providing a reservoir for latent Mtb 8, 14 and coordinating subsequent immune responses.
Both historical cohort studies and contemporary epidemiological studies demonstrate that LTBI is protective against re-infection 3, 15 . The phenomenon of a low-grade infection protecting against subsequent infections with the same pathogen has led to the development of almost all live vaccines currently in use, including those based on bacteria (BCG) or experimental vaccines against parasites (Leishmania) 16 . Likewise, continuous exposure to Plasmodium falciparum, the causative agent of malaria, and maintenance of low-grade parasitemia provides protection against high-density parasitemia and death in adults 17 . This phenomenon is often referred to as "concomitant immunity" 18 or, in the case of malaria, "premunition" 17 . Despite the strong evidence that LTBI confers protection against reinfection, the underlying mechanisms have not been defined, in part due to the lack of a suitable animal model.
Recent studies in mice have shown that intradermally injected Mtb are asymptomatically contained in the draining lymph node for an extended period of time and have used this approach to model LTBI in humans with the goal of understanding failure of containment arising from immune suppression 19, 20 . Because the LTBI mouse model shares many features of latent TB in humans, we hypothesize that it reflects at least a portion of the disease spectrum. Here, we demonstrate that LTBI in mice confers significant protection against subsequent aerosol challenge, in part, by altering the innate immune response to Mtb.
Results

Intradermal Mtb-infection of mice recapitulates key aspects of human LTBI and is contained for up to 1 year.
To establish the model of LTBI, we infected mice intradermally in the ear with 10,000 CFU of a commonly used virulent strain of Mtb, H37Rv 19 . Within 5 days the bacteria trafficked to the ipsilateral superficial cervical lymph nodes which, when extracted, were visibly enlarged. The bacterial burden in the draining lymph node was relatively stable for at least one year ( Figure 1A) with minimal dissemination to the spleen and no dissemination to the lung ( Figure S1 ). Approximately 75% of all spleens investigated were uninfected. If Mtb was detectable, the bacterial load was less than 1000 CFU per spleen (data not shown). We measured the circulating levels of 39 cytokines (including key inflammatory mediators such as IL-6 and TNF, (see Table S1 ) and found that none were significantly altered the first 6 weeks following the establishment of LTBI.
In humans, LTBI is clinically defined by the presence of an Mtb-specific T cell response in the absence of active disease. In LTBI mice, Mtb-specific T cells were detectable in the circulation from day 10 onward without recruitment to the lung parenchyma ( Figure 1B ). Furthermore, for at least one year, the mice displayed no overt systemic symptoms (e.g. weight loss or changes in coat or behavior) nor any local symptoms (including visible inflammation or irritation).
To assess more broadly whether LTBI changes the relative proportions of circulating immune cells, we performed whole blood RNA sequencing on LTBI mice and controls and applied a previously published transcriptome deconvolution approach based on a published deconvolution matrix 21, 22 .
The most pronounced differences were increased frequencies of M1 macrophage type cells and monocytes in LTBI mice ( Figure 1C ). Flow-cytometry analysis of peripheral blood showed subtly but significantly elevated expression of MHC II on CD11b + Ly6C low cells -the "tissue resident macrophages" in the blood compartment 23 -from LTBI mice compared to controls ( Figure 1D ). To assess whether LTBI in humans is associated with changes in circulatory cellularity, we applied the same deconvolution approach to previously published whole blood transcriptome data from uninfected and latently infected humans 24 . In concordance with the mouse data, individuals with LTBI (n = 69) had on average a greater proportion M1 polarized macrophage type cells in the circulation than uninfected individuals (n = 117) ( Figure 1E , S2). Across all samples, the estimated frequencies of M1 and M2 macrophage type cells in humans were inversely correlated with each other ( Figure S3 ).
Taken together, these data indicate that intradermal Mtb-infection of mice recapitulates many key aspects of LTBI in humans, including circulating Mtb-specific T cells in the absence of disease symptoms or elevated levels of pro-inflammatory mediators in peripheral blood. Furthermore, LTBI in mice induces a skewing towards more M1 macrophages in the circulation that we also observed (and to our knowledge has not been previously described) in latently infected humans.
Latently infected mice are strongly protected against aerosol challenge with Mtb and heterologous challenges
To test the hypothesis that LTBI is protective against aerosol infection, we infected mice with 50-100 CFU of Mtb H37Rv 8-10 weeks after the establishment of LTBI and measured bacterial burden in the lung and spleen at 14, 42, and 100 days after challenge. At each of these time points, the bacterial burden in both tissues was significantly lower in LTBI mice compared to controls ( Figure   2A ). We obtained similar results when mice were challenged 10 to 14 days after establishment of LTBI ( Figure S4 ): LTBI mice had on average 18.4-fold (CI: 10.6-26.3) fewer bacteria in the lung as compared to controls measured 6 weeks after aerosol challenge across 6 independent experiments with a total of 60 mice. This level of protection exceeds that of intradermal inoculation with BCG which induces 10-fold protection at day 42 that wanes by day 100 and has minimal impact on bacterial burden within the first two weeks ( Figure S5 ).
Several lines of evidence suggest that human TB typically arises from infection with as few as 1-3 bacteria 11, 12 . We therefore examined the protective effect of LTBI against an "ultra-low dose" (ULD) infection of 1-3 CFU per mouse (see 25 ) . At this dose, mice exhibit a wide range of outcomes, especially at later times, with bacterial burdens in the lung ranging over 4 orders of magnitude ( Figure 2B ). Furthermore, because most mice are infected with a single bacterium, the degree of dissemination can be inferred by measuring spread to the contralateral lobe. Consistent with the 50-100 CFU infections, LTBI mice challenged with 1-3 CFU showed substantially lower bacterial burdens and reduced dissemination in the lung compared to controls for more than 100 days following aerosol challenge ( Figure 2C ). These data demonstrate that LTBI mice are strongly protected against aerosol challenge with Mtb from as early as day 10 until at least 100 days following infection. To our knowledge, the early and sustained protective efficacy of LTBI is among the most profound that has been documented in the C57BL/6 mouse model.
Both adaptive and innate immune responses are required for control of Mtb. We reasoned that if the protective phenotype of the LTBI mice is fully explained by the presence of Mtb specific T cells ( Figure 1B ), these mice should be equally susceptible to other immune challenges that do not share specific antigens with Mtb. To test this, we challenged LTBI and control mice intravenously with 10 5 CFU of Listeria monocytogenes, another intracellular bacterial pathogen. LTBI mice were significantly protected, displaying a greater than 10-fold reduction in bacterial burden in the spleen 48 hours following infection ( Figure 2D ). To confirm and extend these results, we inoculated LTBI and control mice with a non-bacterial immune challenge: a model of metastatic melanoma. Ten days following i.v. injection with melanoma cells, LTBI mice had approximately 10-fold fewer melanoma metastases in the lungs than controls ( Figure 2E ).
The protective phenotype of latent mice is associated with modest tissue inflammation at baseline and an accelerated immune response
These data suggest that the protective phenotype induced by LTBI is mediated by immune mechanisms beyond Mtb-specific T cells. We hypothesized that LTBI modulates the innate immune system at baseline and in response to subsequent challenge leading to more efficient control of bacterial growth.
Prior to aerosol infection
Although LTBI did not induce elevated levels of cytokines in peripheral blood, we hypothesized that it might drive low-level, chronic immune activation in specific tissues. Therefore, we measured cytokine levels in the lungs and spleens of LTBI and control mice prior to aerosol challenge. During the first 6 weeks after establishment of LTBI, the levels of 7 cytokines and chemokines (of 39 assayed) were significantly elevated in the lungs of LTBI mice compared to controls and 5 were elevated in the spleen ( Figure 3A ). The most pronounced changes were increased levels of CCL3, CCL4, and CCL5 in the lung and IFNG and CCL4 in the spleen ( Figure 3A ). Relative levels of the detectable cytokines correlated well across tissues (supplemental Figure S6 ). We did not detect altered concentrations of classic inflammatory cytokines such as IL6 and TNF in any compartment tested. These results suggest that the localized, contained Mtb infection induces a mild and selective increase in local tissue inflammation.
After subsequent challenge
We first assessed the overall responsiveness of myeloid cell populations in the lung by isolating CD11b + cells from LTBI and control mice and stimulating them for 6 hours with TLR-agonists.
Myeloid cells from LTBI mice were more responsive to all stimuli tested as measured by TNF-α secretion ( Figure 3B ). The myeloid populations in the lung of LTBI and control mice were not significantly different ( Figure S7 ).
Next, we investigated the immune response after aerosol Mtb infection by both histology of fixed lung sections and flow cytometry of single cells. In contrast to control mice, which had essentially no histologically detectable response to aerosol Mtb-challenge (100 CFU) at day 14 following infection, LTBI mice exhibited well-formed pulmonary lesions that remained stable for at least 100 days ( Figure 3C ). By day 42, control mice showed significantly more lesions and pulmonary hemorrhages than LTBI mice and this damage continued to progress through day 100 ( Figure 3C , Table S2 ).
To identify the myeloid cells involved in the early response we observed histologically, we measured the recruitment of immune cells to the lung by flow cytometry at early timepoints (days 10-14) after aerosol infection. The magnitude of recruitment to the lung parenchyma of both interstitial macrophages and Mtb-specific T cells, was higher at this early timepoint in LTBI mice compared to controls ( Figure 3D -E). In addition, alveolar macrophages (AMs) from LTBI mice were more highly activated as measured by MHCII expression following aerosol challenge ( Figure 3F ).
These results suggest that a key feature of LTBI is an accelerated, early immune response that reduces the time during which Mtb is able to replicate unchallenged. Furthermore, LTBI mice are able to maintain a protective response with minimal progression of immune pathology for a prolonged period of time.
Heterologous challenges
We hypothesized that heterologous challenges would also be associated with increased myeloid activation. To test this, we infected mice intravenously with 10 7 GFP-expressing Listeria monocytogenes and measured the activation state of splenic macrophages after 2 hours. In concordance with our hypothesis, infected splenic macrophages from LTBI mice upregulated MHCII more strongly than macrophages from controls, suggesting that they were able to respond more robustly to the bacteria ( Figure 3G ). In addition, we evaluated tissue sections from the lung of LTBI or control mice challenged with i.v. melanoma. Strikingly, histiocytic and lymphocytic infiltrates were detectable in the lungs of 3 out of 5 LTBI mice and absent in control mice ( Figure 3H , Table S3 ).
Latent Mtb infection alters the response of alveolar macrophages to aerosol Mtb challenge
Since the protective phenotype in LTBI mice is strongly associated with early recruitment of inflammatory cells to the site of infection ( Figure 3 ) and there is evidence of low-level tissue inflammation prior to challenge ( Figure 3A ), we hypothesized that LTBI affects the activation status and initial response of AMs (the lung resident macrophage and the first cells to be infected with Mtb 16 ).
Prior to aerosol infection
While the total number of CD45 + cells and the fractions of both myeloid and T cells in the lung were unaffected by LTBI ( Figure S7 ), we consistently measured elevated expression of MHCII and FcγRI on AMs ( Figure 4A ), suggesting that their activation state was altered by continuous exposure to low-level inflammation ( Figure 3A ). Expression of CD11c was unaffected by LTBI ( Figure 4A ). To investigate these cells at a more global level, we performed RNA sequencing on AMs isolated from LTBI and control mice. Interestingly, this RNA-seq analysis demonstrated that the transcriptomes of AMs from control and LTBI mice did not differ significantly prior to aerosol challenge ( Figure 4B ).
Following aerosol infection
To assess the immediate response of AMs to infection with Mtb, we challenged mice with a high dose (~3000 CFU) of mEmerald-expressing bacteria. In concordance with previous studies, at 24 hours following infection the bacteria were predominantly contained within AMs 24, 25 . LTBI had no impact on the proportions of cell-types infected ( Figure S8 ). In other studies (currently submitted), we have shown that MTB-infected AMs display a highly delayed pro-inflammatory reponse over the first 10 days of infection 26 The bacterial burden in LTBI mice at 10 days following high-dose (~3000 CFU) aerosol infection, was approximately 3-fold lower than in control mice ( Figure S9 ). The majority of bacteria were in AMs ( Figure 4G ) and significantly fewer AMs were infected in LTBI mice ( Figure 4G ). AMs isolated by BAL from LTBI mice were better able to control Mtb infection ex vivo compared to controls suggesting that the enhanced response of AMs from LTBI mice is at least in part cell-intrinsic.
( Figure 4H ).
Numerous recent studies have suggested that prior or ongoing infection can alter the capacity of innate immune cells to respond to subsequent encounters with pathogens, a phenomenon that has been termed "trained immunity" and has been shown in some cases to be reflected in epigenetic modifications 28 . Therefore, we used ATAC-seq to measure genome-wide changes in chromatin accessibility induced by LTBI. Surprisingly, we observed only modest changes in chromatin accessibility that did not correlate with differentially expressed genes, suggesting that this mechanism cannot account for the enhanced response of AMs to infection ( Figure S10 ).
Taken together, these data suggest that changes in the local, inflammatory environment reprograms the transcriptional responses of AMs and allows for improved control of subsequent aerosol challenges.
The protective phenotype of LTBI mice is diminished by antibiotic therapy
In the absence of long-lasting epigenetic changes, we hypothesized that the protective effect of LTBI results in part from the continuous exposure of innate cells to low-level cytokines secreted by immune cells containing the bacteria and thus would be diminished by antibiotic treatment.
Therefore, we treated LTBI mice and controls for 6 weeks with Isoniazid and Rifampicin prior to aerosol challenge and assessed the impact on bacterial burden. Treatment efficacy was confirmed by culture of lymph node, spleen, and lung lysates from a dedicated set of mice (n = 2-3, two independent experiments, data not shown). Antibiotic treatment significantly diminished the ability of LTBI mice to contain bacterial growth in the lung over the first 6 weeks ( Figure 5A ). At 10 days following aerosol challenge, treated LTBI mice had lower numbers of Mtb-specific T cells in the circulation and in the lung parenchyma compared to untreated LTBI mice ( Figure 5B ). 5B In addition, treatment significantly reduced the expansion of Mtb-specific T cells in response to infection ( Figure   S11 ). These data suggest that the protective phenotype induced by LTBI is dependent on live bacteria.
Discussion
In this study, we have demonstrated that latent infection with virulent Mtb protects mice against subsequent aerosol challenge and that a large component of this protection arises from elevated activation of the innate immune system. Our data suggest that low-level inflammation within the lung enables resident AMs to respond more robustly to infection with Mtb. The increased innate immune response in LTBI mice also confers significant protection against heterologous challenges as diverse as Listeria monocytogenes and metastatic melanoma.
The mouse remains the premier small animal model for immunological research due to the extensive availability of molecular reagents, a large body of historical data, and relatively low cost. Much of our current understanding of TB immunology had its origins in the mouse model before subsequent validation in humans, e.g., the critical roles for CD4 T cells 29 , IFNG 30, 31 , IL-12 32 , and TNF 30 .
Furthermore, the mouse continues to play an essential role in the development of new TB vaccine strategies 33 . The protective effect of LTBI manifests as a reduced bacterial burden as early as 10 days following aerosol challenge that is maintained for at least 3 months after challenge. To our knowledge, this protection is as rapidly acting and durable as any that has been demonstrated in the mouse. Therefore, we argue that the LTBI mouse model offers an important opportunity to identify and dissect mechanisms of protection against TB.
Enhanced innate immune responses resulting from prior exposure to pathogens, a phenomenon termed "trained immunity", is often reflected in epigenetic and transcriptional changes in macrophages and has been shown to be important for protection against Mtb in a model of high dose i.v. BCG vaccination 34 . The protective effect of i.v. BCG depends on the presence of bacteria in the bone marrow, affects the development of myeloid derived macrophages, and is transferrable via macrophages in the absence of live BCG 34 . In the LTBI model presented here, we detect profound changes in the responsiveness of tissue resident AMs, a long-lived cell type derived from fetal monocytes 35 . Furthermore, in the LTBI model, protection depends on live mycobacteria presumably via the continuous interaction between pathogen and host.
Tissue resident AMs from naïve mice have been reported to be niches for Mtb growth, in contrast to myeloid derived macrophages which are better able to control bacterial replication 36 . Mtb-infected AMs from LTBI mice upregulate many of the inflammatory and interferon pathways that are activated in myeloid-derived macrophages but not in Mtb-infected AMs from control mice ( Figure 4E and 19 ).
Thus, LTBI reprograms tissue resident AMs, the cells first infected by inhaled Mtb, to a more bactericidal phenotype that is typically associated with recruited macrophages.
Several mouse models demonstrate that infection or inoculation with live vaccines (including latent
Herpes virus infection, BCG vaccination, and exposure to typical mouse pathogens) confers substantial protection against heterologous challenges by altering the activation state of the innate immune system [37] [38] [39] . Although the potential role in humans of LTBI-mediated heterologous protection has not been rigorously assessed, beneficial heterologous effects of BCG vaccination have been reported: overall mortality of newborns is reduced by more than would be expected from the protection afforded by BCG against TB alone 40 . Both local administration of BCG as well as BCG vaccination restrain melanoma development in humans 41, 42 . BCG-vaccination of mice has been reported to enhance the cytotoxic capacity of isolated macrophages against melanoma cells in vitro 43 . Furthermore, skewing of macrophages from M2 to M1 has been associated with control of melanoma in vivo 13, 14 .
Antibiotic treatment of LTBI mice reduced the numbers of Mtb-specific T cells in the circulation and in the lung parenchyma following aerosol challenge. Surprisingly, treatment also eliminated specific T cell expansion. We hypothesize that eliminating the ongoing contained infection also eliminated the elevated activation of the innate immune system resulting from LTBI and thereby reduced appropriate instruction of the adaptive response. However, more detailed studies are required to elucidate the contributions of memory T cells and reprogrammed macrophages to the protective effect of LTBI.
Preventative antibiotic treatment of patients diagnosed with latent TB is regarded as a cornerstone of TB control. However, preventive therapy is only effective in the first two years after infection and fails to reduce TB incidence if applied without risk-stratification 4, 44 . Counterintuitively, recent epidemiological data suggest that individuals who have been treated for active TB are more susceptible to re-infection and progress more rapidly following re-infection, suggesting that clearing latent infection with preventive therapy might be counterproductive in a high transmission setting 15, 45 .
This phenomenon has been observed for malaria: treatment of low-grade Plasmodium falciparum parasitemia and subsequent loss of natural immunity can lead to hyper-mortality in epidemic regions 46 . In both cases, the protective mechanisms that are undermined by treatment are incompletely understood. A detailed examination of antibiotic treatment in the LTBI mouse model, in conjunction with human studies, may help to uncover these mechanisms and ultimately inform improved clinical treatment of TB in high-incidence settings.
Methods
Mice C57BL/6 were purchased from the Jackson Laboratory. All mice were housed and bred under specific pathogen free conditions at the Center for Infectious Disease Research. All experimental protocols involving animals were approved by the Institutional Animal Care and Use Committee of the Center for Infectious Disease Research.
Tissue Culture
Alveolar macrophages were cultured in complete RPMI [cRPMI; plus 10%(vol/vol) FBS, 2 mM lglutamine, penicillin, and streptomycin] for 24 hours after isolation by bronchoalveolar lavage (BAL).
In vitro infections were performed in cRPMI without antibiotics in biological triplicate (cells from independent mice). The bacterial load at day 5 was determined by plating serial dilutions of cells lysed in 1% Triton-X and diluted in 0.1% Tween-80 PBS.
Establishment of LTBI via intradermal infection of the ear, aerosol Infections, and enumeration of bacterial load
Intradermal infections to establish were performed as described previously 19 with the following modifications: 10,000 CFU of Mtb (H37Rv) in logarithmic phase growth in 10 μL PBS were injected intradermally into mice anaesthetized with Ketamine using a 10μl Hamilton Syringe. In some experiments, MTB Erdman strain was used with same results. For aerosol infections, a frozen stock of Kanamycin-resistant Mtb H37Rv was diluted and used to infect mice in an aerosol infection chamber (Glas-Col). For high dose mEmerald infections, a deposition of 3000-5000 CFU was targeted. For Ultra low dose infections, a deposition of 1-3 CFU was targeted accepting a rate of approximately 30% uninfected animals. Bacterial load in the lungs was determined by plating serial dilutions from homogenized lungs. MTB was plated on Kanamycin-containing plates and antibioticfree plates to distinguish the origin of the infection (intradermal versus aerosol infection).
Heterologous challenges
For experiments with bacterial burden as the endpoint, 10 5 Listeria monocytogenes were injected i.v. and CFU in the spleen measured 48 hours later. For experiments with an early response as endpoint, mice were infected with 10 7 Listeria monocytogenes and sacrificed 2 hours after i.v.
infection. The B16-F10 (ATCC® CRL-6475™) melanoma cell line was purchased from ATCC and expanded according to the supplier's instructions. For the melanoma challenges, 10 5 melanoma cells per mouse were injected i.v. After 10 days, mice were sacrificed, lungs were extracted and bleached in Fekete's solution following a published protocol 47 , and the metastases were counted by an investigator blinded to the identity of each mouse.
Cell Isolation, Analysis, and Sorting
For i.v. labeling, PE labeled CD45.2 was injected i.v. 10 minutes prior to harvest. Single-cell suspensions of lung cells were prepared by Liberase Blendzyme 3 (Roche) digestion of perfused lungs as previously described 48 . Cells from spleens were prepared as previously described (Spleen digestion protocol, Miltenyi Biotec). Fc-receptors were blocked with anti-CD16/32 (clone 2.4G2).
Cells were suspended in 1×PBS (pH 7.4) containing 2.5% FBS and stained at saturating conditions with antibodies against various epitopes (see Table S4 ). Samples were fixed in 2% (vol/vol) paraformaldehyde and analyzed using a LSRII flow cytometer (BD) and FlowJo software (Tree Star, Inc.). Previously published gating strategies were followed 49, 50 . In some experiments, alveolar macrophages were isolated from suspensions of lung cells using a BD Aria II cell sorter. Gating strategies are presented in Supplemental Figure 12 
CD11b + cell enrichment and ex vivo stimulation
Single cell suspensions prepared as described above from pooled lungs and spleens were positively enriched for CD11b + using magnetic beads (Miltenyi Biotec). The cells were re-stimulated with TLRagonists (LPS 10 ng/mL, PAM3 300 ng/mL, R848 100 ng/mL) and supernatants were collected 6 hours after re-stimulation and assayed by ELISA for TNF-α. Tetramer staining on single-cell preparations was carried out as described previously 51 .
Measurement of total protein
Detection of Mtb-Specific T Cells
Immunohistochemistry
Tissue sections were formalin-fixed and paraffin-embedded. H&E Staining was carried out using standard protocols. An independent, board-certified pathologist reviewed and scored the tissue sections, blinded to their experimental group membership.
RNAseq
RNA isolation was performed using TRIzol (Invitrogen), two sequential chloroform extractions, Glycoblue carrier (Thermo Fisher), isopropanol precipitation, and washes with 75% ethanol. RNA Bigwig files for each biological group were generated by running MACS2 56 (https://github.com/taoliu/MACS) peak calling on combined alignments from all samples in the group and outputting a normalized bedgraph file followed by file conversion using the bedGraphToBigWig program (genome.ucsc.edu). The R package DiffBind 58 was used to define consensus peak regions across samples and assign counts. Differential peak counts and significance were computed using the R package edgeR 59, 60 . Raw and processed data are deposited in GEO (GSE126355).
Whole blood transcriptome deconvolution analysis
Computational deconvolution of cell type proportion from whole-blood gene expression data was performed as previously described 61 . This approach used the assumption that whole-blood gene 
Statistical Analysis
Significance was determined using an unpaired two-tailed Student's t-test unless otherwise specified.
Data Availability
Raw and processed RNA-seq and ATAC-seq data are deposited in GEO (GSE126355) ( Figure 1A , 
Supplementary Figure 5: Protective efficacy of BCG Pasteur
Mice were immunized intradermally with 1x10 6 CFU BCG Pasteur and challenged with 100 CFU Mtb H37Rv after 2 months. Bacterial burden in the lung was measured by CFU assay at days 10, 42, and 100 following aerosol challenge (n = 4-5 mice/group/time-point). 
Supplementary Figure 6: Correlation between cytokines levels in lungs and spleens of LTBI
